Acne
Dermatology 0 original drugsDermatology indication. Acne has 0 FDA-approved novel treatments, with 39 active industry clinical trials. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Phase 3 Readouts Pro
5 active Phase 3 trials with confidence-graded completion dates.
Q3 2028
1% Clascoterone Cream
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Estimated · fresh NCT07457294
Unlock 2 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Acne Treatments by Mechanism
Top 3 mechanisms across 11 industry trials with a known mechanism of action.
Retinoid
9 trials 1 active 5 sponsors
Androgen Receptor Inhibitor
1 trials 1 active 1 sponsor
Sulfone
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Acne Clinical Pipeline by Phase
278 industry-sponsored trials across 83 sponsors
Showing 52 of 52 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Integrative Skin Science and Research | Sarecycline | — | RECRUITING | 2027-04 | NCT07544251 |
| Sun Pharmaceutical Industries Limited | Winlevi (Clascoterone) cream 1% | — | ACTIVE NOT RECRUITING | 2026-03 | NCT06425900 |
| Bausch Health Americas, Inc. | CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%. | — | NOT YET RECRUITING | 2027-12 | NCT07524946 |
| Sun Pharmaceutical Industries Limited | Winlevi (clascoterone) 1% cream | — | COMPLETED | 2025-02-12 | NCT06415279 |
| Sun Pharmaceutical Industries Limited | Winlevi (clascoterone) 1% & Adapalene 0.3% gel | — | COMPLETED | 2024-10-29 | NCT06336603 |
| Sun Pharmaceutical Industries Limited | Winlevi (clascoterone) 1% & Duac gel | — | COMPLETED | 2024-07-10 | NCT06336629 |
| Sun Pharmaceutical Industries Limited | Winlevi (clascoterone) 1% cream | — | COMPLETED | 2024-04-17 | NCT06415305 |
| Sun Pharmaceutical Industries Limited | Winlevi (clascoterone) 1% cream | — | COMPLETED | 2023-12-16 | NCT06415292 |
| Galderma R&D | Trifarotene Cream | — | COMPLETED | 2023-02-08 | NCT04856904 |
| Galderma R&D | Trifarotene Cream | — | COMPLETED | 2022-12-15 | NCT05089708 |
| Galderma R&D | Trifarotene cream | — | COMPLETED | 2021-04-26 | NCT04451330 |
| Vichy Laboratoires | Salicylic Acid | — | COMPLETED | 2020-02-17 | NCT03832647 |
| Sun Pharmaceutical Industries Limited | Isotretinoin | Retinoid [EPC] | COMPLETED | 2018-04 | NCT02457520 |
| Almirall, S.A. | dapsone gel | — | COMPLETED | 2018-03-09 | NCT02959970 |
| Galderma R&D | ABPO Forte Gel | — | COMPLETED | 2017-06-05 | NCT02735421 |
| Galderma R&D | Product A | — | COMPLETED | 2017-04-04 | NCT02755545 |
| Galderma R&D | Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel | — | COMPLETED | 2017-03-28 | NCT02899000 |
| BioPharmX, Inc. | Minocycline | — | COMPLETED | 2016-04 | NCT02695446 |
| Galderma R&D | Benzoyl Peroxide | Retinoid [EPC] | COMPLETED | 2016-01 | NCT02589405 |
| GSK | Duac® fixed dose combination gel | — | COMPLETED | 2015-12-17 | NCT02557399 |
| Galderma R&D | — | — | COMPLETED | 2015-06 | NCT02307266 |
| Galderma R&D | Adapalene/benzoyl peroxide gel, 0.1%/2.5% | — | COMPLETED | 2015-02 | NCT02249104 |
| GSK | Clindamycin + BPO | — | COMPLETED | 2014-09-08 | NCT02058628 |
| AbbVie | Dapsone Gel | — | COMPLETED | 2014-06 | NCT02032407 |
| Galderma R&D | Adapalene/BPO Gel | — | COMPLETED | 2014-03 | NCT01951417 |
| Galderma R&D | Epiduo Gel | — | COMPLETED | 2012-05 | NCT01522456 |
| Galderma R&D | adapalene/benzoyl peroxide | — | COMPLETED | 2011-08 | NCT01138735 |
| Medicis Global Service Corporation | Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide | — | COMPLETED | 2011-07 | NCT01206348 |
| AbbVie | Dapsone plus Adapalene | — | COMPLETED | 2011-06 | NCT01231334 |
| Galderma Brasil Ltda. | Adapalene-BPO Gel | — | COMPLETED | 2011-03 | NCT01149330 |
| Galderma R&D | Adapalene 0.1% and Benzoyl Peroxide 2.5% gel | — | COMPLETED | 2011-01 | NCT01209949 |
| Bausch Health Americas, Inc. | Dapsone plus Tretinoin Gel | — | COMPLETED | 2010-12 | NCT01313728 |
| Galderma R&D | Epiduo gel | — | COMPLETED | 2010-08 | NCT01188538 |
| Stiefel, a GSK Company | Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene | — | COMPLETED | 2010-04 | NCT01016977 |
| Janssen-Cilag Ltd.,Thailand | Ethinyl estradiol/Norgestimate (EE/NGM) | — | COMPLETED | 2010-03 | NCT01466673 |
| Stiefel, a GSK Company | — | — | COMPLETED | 2010-01-01 | NCT01706250 |
| Stiefel, a GSK Company | — | — | COMPLETED | 2009-12 | NCT02524665 |
| Stiefel, a GSK Company | MAXCLARITY II (2.5% BPO) Foam Cleanser | — | COMPLETED | 2009-11-20 | NCT01706263 |
| Stiefel, a GSK Company | Clindamycin and benzoyl peroxide gel (Duac® Topical Gel) | — | COMPLETED | 2009-11 | NCT00964223 |
| Bausch Health Americas, Inc. | Tretinoin Facial Gel | — | COMPLETED | 2009-10 | NCT00952523 |
| Stiefel, a GSK Company | Clindamycin and BPO 5% gel | — | COMPLETED | 2009-09 | NCT01015638 |
| Bausch Health Americas, Inc. | benzoyl peroxide wash | — | COMPLETED | 2009-09 | NCT00907257 |
| AbbVie | Dapsone | Sulfone [EPC] | COMPLETED | 2009-09 | NCT00834210 |
| Stiefel, a GSK Company | clindamycin and benzoyl peroxide | — | COMPLETED | 2009-08 | NCT00964366 |
| AbbVie | Dapsone; Tretinoin | — | COMPLETED | 2009-08 | NCT00835198 |
| Stiefel, a GSK Company | BENZOYL PEROXIDE/ CLINDAMYCIN | — | COMPLETED | 2009-06 | NCT00887484 |
| Stiefel, a GSK Company | Clindamycin and benzoyl peroxide | — | COMPLETED | 2009-06 | NCT00926367 |
| Bausch Health Americas, Inc. | Tretinoin gel | — | COMPLETED | 2009-05 | NCT00919191 |
| Stiefel, a GSK Company | Epiduo Gel | — | COMPLETED | 2009-04-24 | NCT00757523 |
| Warner Chilcott | Doxycycline hyclate (Doryx) | — | COMPLETED | 2008-09 | NCT00635609 |
| Galderma R&D | Adapalene | Retinoid [EPC] | COMPLETED | 2008-08 | NCT00660985 |
| Bausch Health Americas, Inc. | Adapalene Gel | — | COMPLETED | 2008-02 | NCT00714714 |
Showing 88 of 88 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | Clascoterone | Androgen Receptor Inhibitor [EPC] | RECRUITING | 2026-10 | NCT06403501 |
| Galderma R&D | Trifarotene | Retinoid [EPC] | RECRUITING | 2026-12-31 | NCT07186413 |
| Eurofarma Laboratorios S.A. | Experimental drug | — | NOT YET RECRUITING | 2027-02 | NCT06905210 |
| Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | 1% Clascoterone Cream | — | NOT YET RECRUITING | 2028-08-07 | NCT07457294 |
| Equipmed USA LLC | — | — | NOT YET RECRUITING | 2025-03 | NCT06602284 |
| Ascletis Pharmaceuticals Co., Ltd. | ASC40 | — | COMPLETED | 2025-11-12 | NCT06248008 |
| Ascletis Pharmaceuticals Co., Ltd. | ASC40 | — | COMPLETED | 2025-05-19 | NCT06192264 |
| Dermata Therapeutics | DMT310 | — | COMPLETED | 2025-03-31 | NCT06090721 |
| Teva Pharmaceuticals USA | Trifarotene 0.005 % Topical Cream | — | COMPLETED | 2023-05-09 | NCT05550337 |
| Cutia Therapeutics (Shanghai) Co., Ltd | FMX101 | — | COMPLETED | 2022-09-27 | NCT04960930 |
| Bausch Health Americas, Inc. | IDP-126 Gel | — | COMPLETED | 2021-03-18 | NCT04214652 |
| Bausch Health Americas, Inc. | IDP-126 Gel | — | COMPLETED | 2021-01-18 | NCT04214639 |
| Bausch Health Americas, Inc. | IDP-120 Gel | — | COMPLETED | 2020-05-07 | NCT03664752 |
| Bausch Health Americas, Inc. | IDP-120 Gel | — | COMPLETED | 2020-03-23 | NCT03664739 |
| Balmoral Medical company | GDC 268 Lotion | — | COMPLETED | 2020-02-17 | NCT03717506 |
| Lee's Pharmaceutical Limited | Adapalene Gel | — | COMPLETED | 2020-02-13 | NCT03615768 |
| Torrent Pharmaceuticals Limited | Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) | — | COMPLETED | 2020-02-03 | NCT04015375 |
| Sol-Gel Technologies, Ltd. | S6G5T-3 | — | COMPLETED | 2019-12-31 | NCT03761784 |
| Galderma R&D | Trifarotene | Retinoid [EPC] | COMPLETED | 2019-12-23 | NCT03915860 |
| Sol-Gel Technologies, Ltd. | S6G5T-3 | — | COMPLETED | 2019-10-23 | NCT03761810 |
| Akorn, Inc. | Clindamycin 1% Gel | — | COMPLETED | 2019-04-22 | NCT03522441 |
| Aleor Dermaceuticals Limited | Adapalene Gel 0.3% | — | COMPLETED | 2019-02-16 | NCT03650361 |
| Padagis LLC | Adapalene and Benzoyl Peroxide Topical Gel | — | COMPLETED | 2018-09-30 | NCT03393494 |
| Vyne Therapeutics Inc. | FMX101 | — | COMPLETED | 2018-09-04 | NCT03271021 |
| Cassiopea SpA | CB-03-01 cream, 1% | — | COMPLETED | 2018-08-31 | NCT02682264 |
| Bausch Health Americas, Inc. | IDP-123 Lotion | — | COMPLETED | 2018-07-24 | NCT03168334 |
| Bausch Health Americas, Inc. | IDP-123 Lotion | — | COMPLETED | 2018-06-07 | NCT03168321 |
| Dr. Reddy's Laboratories Limited | DFD-03 (0.1% tazarotene) Lotion | — | COMPLETED | 2018-05-14 | NCT03292640 |
| Dermira, Inc. | Olumacostat Glasaretil Gel, 5.0% | — | COMPLETED | 2018-04-27 | NCT03127956 |
| Dr. Reddy's Laboratories Limited | DFD-03 | — | COMPLETED | 2018-04-19 | NCT03290027 |
| Cassiopea SpA | CB-03-01 cream, 1% | — | COMPLETED | 2018-04-11 | NCT02608450 |
| Cassiopea SpA | CB-03-01 cream, 1% | — | COMPLETED | 2018-02-21 | NCT02608476 |
| Galderma R&D | Adapalene 0.3% / BPO 2.5% gel | — | COMPLETED | 2018-01-10 | NCT02932267 |
| Dermira, Inc. | Olumacostat Glasaretil Gel, 5.0% | — | COMPLETED | 2017-12-21 | NCT03073486 |
| Dermira, Inc. | Olumacostat Glasaretil Gel, 5.0% | — | COMPLETED | 2017-11-28 | NCT03028363 |
| Galderma R&D | CD5789 (trifarotene) 50μg/g cream | — | COMPLETED | 2017-11-14 | NCT02566369 |
| Vyne Therapeutics Inc. | FMX-101, 4% minocycline foam | — | COMPLETED | 2017-10-13 | NCT02815280 |
| Vyne Therapeutics Inc. | FMX-101, 4% minocycline foam | — | COMPLETED | 2017-10-13 | NCT02815267 |
| AOBiome LLC | B244 | — | COMPLETED | 2017-07-19 | NCT02832063 |
| Fougera Pharmaceuticals Inc. | Tazarotene Cream 0.1% | — | COMPLETED | 2017-05-31 | NCT02886715 |
| Novan, Inc. | SB204 4% | — | COMPLETED | 2017-04 | NCT02798120 |
| Bausch Health Americas, Inc. | IDP 121 Lotion | — | COMPLETED | 2017-02-23 | NCT02965456 |
| Galderma R&D | CD5789 (trifarotene) | — | COMPLETED | 2017-02-23 | NCT02189629 |
| Bausch Health Americas, Inc. | IDP-121 Lotion | — | COMPLETED | 2017-02-22 | NCT02932306 |
| Galderma R&D | CD5789 (trifarotene) 50µg/g Cream | — | COMPLETED | 2017-02-07 | NCT02556788 |
| Almirall, S.A. | Sarecycline | — | COMPLETED | 2017-02-01 | NCT02320149 |
| Almirall, S.A. | Sarecycline | — | COMPLETED | 2017-01-12 | NCT02322866 |
| Novan, Inc. | SB204 4% | — | COMPLETED | 2016-12 | NCT02667444 |
| Novan, Inc. | SB204 4% | — | COMPLETED | 2016-12 | NCT02672332 |
| Seegpharm S.A. | Dapsone 5.0% Gel (SEEGPharm) | — | COMPLETED | 2016-11 | NCT02865005 |
| Zydus Lifesciences Limited | Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel | — | COMPLETED | 2016-09-28 | NCT02005666 |
| Almirall, S.A. | Sarecycline | — | COMPLETED | 2016-08-26 | NCT02413346 |
| Padagis LLC | Clindamycin and Benzoyl Peroxide Gel (combination) | — | COMPLETED | 2016-04 | NCT02515305 |
| Actavis Inc. | Epiduo® Forte Gel | — | COMPLETED | 2016-04 | NCT02651220 |
| Glenmark Pharmaceuticals Ltd. India | Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel | — | COMPLETED | 2015-11 | NCT02465632 |
| Actavis Inc. | Onexton | — | COMPLETED | 2015-10 | NCT02616614 |
| G & W Laboratories Inc. | Vehicle | — | COMPLETED | 2015-07 | NCT02160678 |
| Almirall, S.A. | Dapsone Gel | — | COMPLETED | 2014-10 | NCT01974323 |
| Almirall, S.A. | Dapsone Gel | — | COMPLETED | 2014-10 | NCT01974141 |
| Galderma R&D | GK530G | — | COMPLETED | 2014-10 | NCT02073448 |
| Actavis Inc. | Tazarotene (Fabior™) | — | COMPLETED | 2014-09 | NCT02267746 |
| Galderma R&D | GK530G | — | COMPLETED | 2014-08 | NCT01910064 |
| Spear Pharmaceuticals | Tretinoin | Retinoid [EPC] | COMPLETED | 2014-06 | NCT02249767 |
| GSK | Duac™Once Daily Gel | — | COMPLETED | 2014-04 | NCT01915732 |
| Galderma R&D | CD0271 0.3% / CD1579 2.5% | — | COMPLETED | 2014-03 | NCT01880320 |
| Galderma R&D | Epiduo/Tactuo | — | COMPLETED | 2013-07 | NCT01474590 |
| Bausch Health Americas, Inc. | ACYC | — | COMPLETED | 2013-05 | NCT01701024 |
| KLOX Technologies Inc. | — | — | COMPLETED | 2013-04 | NCT01584674 |
| Padagis LLC | Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% | — | COMPLETED | 2013-02 | NCT01796665 |
| Watson Laboratories, Inc. | Clindamycin Phosphate / Benzoyl Peroxide Gel | — | COMPLETED | 2012-12 | NCT01788384 |
| GSK | GSK2585823(CLDM 1%-BPO 3% gel) | — | COMPLETED | 2012-08-02 | NCT01445301 |
| Padagis LLC | Adapalene and Benzoyl Peroxide Gel | — | COMPLETED | 2012-08 | NCT02525549 |
| GSK | GI148512 | — | COMPLETED | 2012-04 | NCT01400932 |
| Stiefel, a GSK Company | Tazarotene Foam | — | COMPLETED | 2010-11-01 | NCT01017120 |
| Stiefel, a GSK Company | Tazarotene foam | — | COMPLETED | 2010-11 | NCT01017146 |
| Padagis LLC | Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo) | — | COMPLETED | 2010-10 | NCT01138514 |
| Spear Pharmaceuticals | Tretinoin | Retinoid [EPC] | COMPLETED | 2010-10 | NCT01243450 |
| Bayer | EE20/Drospirenone (YAZ, BAY86-5300) | — | COMPLETED | 2010-05 | NCT00818519 |
| Galderma R&D | Adapalene/ BPO gel with Lymecycline capsules | — | COMPLETED | 2010-04 | NCT01014689 |
| Spear Pharmaceuticals | Tretinoin microsphere 0.1% | — | COMPLETED | 2010-04 | NCT01135069 |
| Igefarma Laboratorios S.A. | application of the topic gel | — | COMPLETED | 2010-01 | NCT00838812 |
| Galderma R&D | Adapalene BPO Gel standard daily overnight application | — | COMPLETED | 2009-09 | NCT00883233 |
| Stiefel, a GSK Company | clindamycin / benzoyl peroxide gel | — | COMPLETED | 2009-09 | NCT00776919 |
| Galderma R&D | Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel | — | COMPLETED | 2009-07 | NCT00687908 |
| Stiefel, a GSK Company | CTGel/ BPO Wash | — | COMPLETED | 2009-06-01 | NCT00891982 |
| Stiefel, a GSK Company | CT Gel | — | COMPLETED | 2009-04 | NCT00689117 |
| Galderma R&D | Adapalene BPO Gel associated with Doxycyline Hyclate | — | COMPLETED | 2009-02 | NCT00688064 |
| Aurobindo Pharma Ltd | Adapalene 0.1% Gel | — | WITHDRAWN | 2021-01 | NCT04329403 |
Showing 76 of 76 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Sanofi | Acne mRNA vaccine | — | RECRUITING | 2028-11-30 | NCT06316297 |
| Sanofi | Acne mRNA vaccine | — | RECRUITING | 2029-06-19 | NCT07013747 |
| Biofrontera Inc. | — | — | ACTIVE NOT RECRUITING | 2025-08-22 | NCT05080764 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | HB0043 | — | NOT YET RECRUITING | 2026-10-27 | NCT07449156 |
| Jiangxi Kvvit Pharmaceutical Co., Ltd. | KR230109 cream 0.025% | — | NOT YET RECRUITING | 2026-10-30 | NCT07345390 |
| Lallemand Health Solutions | — | — | COMPLETED | 2024-09-18 | NCT05755256 |
| Ascletis Pharmaceuticals Co., Ltd. | ASC40 25mg | — | COMPLETED | 2023-04-10 | NCT05104125 |
| Bausch Health Americas, Inc. | IDP-126 Gel | — | COMPLETED | 2022-09-28 | NCT04892706 |
| Novartis | LYS006 20 mg | — | COMPLETED | 2022-02-24 | NCT03497897 |
| Vanda Pharmaceuticals | Imsidolimab | — | COMPLETED | 2022-02-01 | NCT04856917 |
| Dermata Therapeutics | DMT310 | — | COMPLETED | 2020-05-04 | NCT04106778 |
| Vyne Therapeutics Inc. | 3% Minocycline Foam | — | COMPLETED | 2020-02-28 | NCT04104685 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | ALA 2.5% | — | COMPLETED | 2020-01-20 | NCT04018885 |
| Botanix Pharmaceuticals | BTX 1503 | — | COMPLETED | 2019-08-16 | NCT03573518 |
| Bausch Health Americas, Inc. | IDP-126 Gel | — | COMPLETED | 2019-04-23 | NCT03170388 |
| Dermata Therapeutics | DMT310 | — | COMPLETED | 2018-12-30 | NCT03536637 |
| Novartis | CJM112 | — | COMPLETED | 2018-08-01 | NCT02998671 |
| BioPharmX, Inc. | Minocycline | — | COMPLETED | 2018-06-01 | NCT02946788 |
| Therapeutics, Inc. | UHE-101 Cream | — | COMPLETED | 2018-05-31 | NCT03307577 |
| Dr. Reddy's Laboratories Limited | DFD-03 Lotion, 0.1% | — | COMPLETED | 2018-05-18 | NCT03341910 |
| Dr. Reddy's Laboratories Limited | Tazarotene Lotion, 0.1% | — | COMPLETED | 2018-04-30 | NCT03599193 |
| Cassiopea SpA | cortexolone 17α-propionate | — | COMPLETED | 2018-03-21 | NCT02720627 |
| Sol-Gel Technologies, Ltd. | S6G5T-3 | — | COMPLETED | 2017-10 | NCT02661958 |
| Lee's Pharmaceutical Limited | Adapalene + Clindamycin Hydrochloride | — | COMPLETED | 2017-07-31 | NCT02593383 |
| LEO Pharma | LEO43204 | — | COMPLETED | 2017-04 | NCT02575950 |
| BioPharmX, Inc. | BPX-01 1% Minocycline Topical Gel | — | COMPLETED | 2017-03-24 | NCT02815332 |
| Xenon Pharmaceuticals Inc. | XPF-005 | — | COMPLETED | 2017-02-16 | NCT02656043 |
| Sun Pharmaceutical Industries, Inc. | ADPS topical product | — | COMPLETED | 2017-01-24 | NCT02935036 |
| Galderma R&D | CD5024 1% cream | — | COMPLETED | 2016-11-02 | NCT03034460 |
| Bausch Health Americas, Inc. | IDP-120 Gel | — | COMPLETED | 2016-08-31 | NCT03003247 |
| Maruho Co., Ltd. | Omiganan (CLS001) Topical Gel | — | COMPLETED | 2016-08 | NCT02571998 |
| Bausch Health Americas, Inc. | IDP-123 Lotion | — | COMPLETED | 2016-07 | NCT02938494 |
| BioPharmX, Inc. | BPX-01, 1% Topical Gel | — | COMPLETED | 2016-06 | NCT02709096 |
| Braintree Laboratories | BLI1100-1 | — | COMPLETED | 2016-06 | NCT02604680 |
| Dermira, Inc. | Olumacostat Glasaretil | — | COMPLETED | 2016-04 | NCT02431052 |
| AOBiome LLC | B244 | — | COMPLETED | 2016-03-01 | NCT02656485 |
| Next Science TM | Next Science Acne Gel | — | COMPLETED | 2015-09 | NCT02404285 |
| Novan, Inc. | SB204 2% | — | COMPLETED | 2015-06 | NCT02242760 |
| Mimetica Pty Limited | 0.75% (w/w) MTC896 Gel Once Daily | — | COMPLETED | 2015-01 | NCT02293018 |
| Maruho Co., Ltd. | CLS001 Topical Gel | — | COMPLETED | 2014-11 | NCT02066545 |
| Galderma R&D | CD1579 2.5% | — | COMPLETED | 2014-10 | NCT02073461 |
| Dermira, Inc. | Olumacostat Glasaretil Gel, 7.5% | — | COMPLETED | 2014-06 | NCT01936324 |
| Intrepid Therapeutics, Inc. | CB-03-01 | — | COMPLETED | 2014-02 | NCT01631474 |
| Intrepid Therapeutics, Inc. | cortexolone 17α-propionate | — | COMPLETED | 2013-11 | NCT01831960 |
| Novan, Inc. | NVN1000 1% Gel | — | COMPLETED | 2013-11 | NCT01844752 |
| Braintree Laboratories | BLI1100 | — | COMPLETED | 2013-11 | NCT01815450 |
| Galderma R&D | CD5789 25 µg/g cream | — | COMPLETED | 2013-07-24 | NCT01616654 |
| Vyne Therapeutics Inc. | Topical Minocycline Foam FXFM244 | — | COMPLETED | 2013-06 | NCT01362010 |
| XOMA (US) LLC | gevokizumab | — | COMPLETED | 2013-04 | NCT01498874 |
| Dermira, Inc. | Lemuteporfin | — | COMPLETED | 2013-03 | NCT01490736 |
| Almirall, S.A. | 50 mg P005672-HCl | — | COMPLETED | 2012-11-16 | NCT01628549 |
| Johnson & Johnson | RA-18C3 | — | COMPLETED | 2012-10-31 | NCT01474798 |
| AndroScience Corp | ASC-J9 | — | COMPLETED | 2012-07 | NCT01289574 |
| LEO Pharma | marketed topical retinoid | — | COMPLETED | 2012-04 | NCT01461655 |
| Photocure | Visonac PDT | — | COMPLETED | 2012-04 | NCT01347879 |
| Anterios Inc. | ANT-1207 | — | COMPLETED | 2012-04 | NCT01293552 |
| Bausch Health Americas, Inc. | 1.2% JNJ 10229570-AAA | — | COMPLETED | 2012-03-31 | NCT01326780 |
| Galderma R&D | CD2475/101 40 mg | — | COMPLETED | 2012-01-03 | NCT01320033 |
| Novan, Inc. | NVN1000 | — | COMPLETED | 2011-12 | NCT01556698 |
| Dow Pharmaceutical Sciences | Low Strength IDP-107 | — | COMPLETED | 2011-12 | NCT01194375 |
| Braintree Laboratories | BLI1100 | — | COMPLETED | 2011-04 | NCT01241331 |
| Clinuvel Pharmaceuticals Limited | Afamelanotide | — | COMPLETED | 2011-03-08 | NCT04943159 |
| Photocure | Area cleaned with saline water and occluded with Tegaderm | — | COMPLETED | 2011-01 | NCT01160848 |
| Oplon-Pure Science Ltd. | — | — | COMPLETED | 2010-10 | NCT01180543 |
| Galderma R&D | Epiduo vehicle gel | — | COMPLETED | 2010-09 | NCT01106807 |
| Oplon-Pure Science Ltd. | — | — | COMPLETED | 2010-06 | NCT01179633 |
| Photocure | Visonac PDT (MAL PDT) | — | COMPLETED | 2010-03 | NCT00933543 |
| Aria Aesthetics Inc. | Topical oxygen | — | COMPLETED | 2010-01 | NCT00991198 |
| Bausch Health Americas, Inc. | Retin-A Micro 0.04% facial acne treatment | — | COMPLETED | 2009-12 | NCT00907335 |
| Stiefel, a GSK Company | Benzoyl peroxide gel | — | COMPLETED | 2009-03 | NCT00713609 |
| Dow Pharmaceutical Sciences | Low Strength IDP-107 | — | COMPLETED | 2009-03 | NCT00666900 |
| Photocure | Methyl aminolevulinate (MAL) PDT | — | COMPLETED | 2008-12 | NCT00673933 |
| Warner Chilcott | Doxycycline 0.6 mg/kg/day | — | COMPLETED | 2008-11 | NCT00612573 |
| BioMimetix JV, LLC | BMX-010 0.3% | — | TERMINATED | 2020-08-31 | NCT03752242 |
| Thesan Pharmaceuticals, Inc. | Vehicle | — | WITHDRAWN | 2017-02 | NCT02796066 |
| Pfizer | PF-05175157 | — | WITHDRAWN | 2014-10 | NCT02100527 |
Showing 62 of 62 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Sagimet Biosciences Inc. | TVB-3567 | — | RECRUITING | 2027-01 | NCT06989840 |
| Sun Pharmaceutical Industries, Inc. | Tretinoin Gel Microsphere, 0.04% | — | COMPLETED | 2025-12-15 | NCT07469228 |
| Pfizer | PF-07905428 | — | COMPLETED | 2025-12-04 | NCT06671834 |
| Sun Pharmaceutical Industries, Inc. | Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% | — | COMPLETED | 2024-09-03 | NCT06673641 |
| Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | Clascoterone Cream 1% | — | COMPLETED | 2024-08-12 | NCT06454708 |
| Sun Pharmaceutical Industries, Inc. | Trifarotene Cream 0.005% | — | COMPLETED | 2024-06-20 | NCT06733402 |
| Sanofi | ORG101 - Experimental 1 | — | COMPLETED | 2023-11-27 | NCT05131373 |
| Sun Pharmaceutical Industries, Inc. | Trifarotene Cream 0.005% | — | COMPLETED | 2023-07-13 | NCT06063473 |
| Suzhou Kintor Pharmaceutical Inc, | GT20029 Gel | — | COMPLETED | 2022-10-27 | NCT05428449 |
| Suzhou Kintor Pharmaceutical Inc, | GT20029 | — | COMPLETED | 2022-08-15 | NCT06468579 |
| Johnson & Johnson Consumer Inc. (J&JCI) | Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) | — | COMPLETED | 2021-09-13 | NCT05012735 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | ALA 5% | — | COMPLETED | 2021-07-30 | NCT04044898 |
| Boston Pharmaceuticals | BOS-356 | — | COMPLETED | 2020-11-11 | NCT04163263 |
| Sol-Gel Technologies, Ltd. | S6G5T-3 | — | COMPLETED | 2020-02-06 | NCT04059523 |
| Sun Pharmaceutical Industries, Inc. | Clindamycin Phosphate | Retinoid [EPC] | COMPLETED | 2019-12-14 | NCT04321070 |
| Naked Biome, Inc. | NB01 | — | COMPLETED | 2019-09-30 | NCT03709654 |
| Sun Pharmaceutical Industries, Inc. | CLPG Topical Gel 1% | — | COMPLETED | 2019-09-17 | NCT04134273 |
| Bausch Health Americas, Inc. | IDP-126 Gel | — | COMPLETED | 2019-06-19 | NCT03653403 |
| Vyne Therapeutics Inc. | FMX101 vehicle | — | COMPLETED | 2019-02-11 | NCT03743038 |
| Naked Biome, Inc. | NB01 | — | COMPLETED | 2018-06-18 | NCT03450369 |
| Sun Pharmaceutical Industries, Inc. | DPSG 7.5% | — | COMPLETED | 2017-01-16 | NCT03132194 |
| Bausch Health Americas, Inc. | IDP-123 Lotion | — | COMPLETED | 2016-12 | NCT02849873 |
| Bausch Health Americas, Inc. | IDP-120 Gel | — | COMPLETED | 2016-10 | NCT02850003 |
| Bausch Health Americas, Inc. | IDP-121 Lotion | — | COMPLETED | 2016-09 | NCT02849860 |
| Novan, Inc. | SB204 4% | — | COMPLETED | 2016-08 | NCT02801903 |
| Sun Pharmaceutical Industries, Inc. | Test. | — | COMPLETED | 2016-06 | NCT02929719 |
| Sun Pharmaceutical Industries, Inc. | Adapalene/BP gel, 0.3%/2.5% | — | COMPLETED | 2016-02 | NCT02709902 |
| Novan, Inc. | SB204 4% | — | COMPLETED | 2015-12 | NCT02581072 |
| Sun Pharmaceutical Industries, Inc. | Clindamycin and Benzoyl Peroxide Gel 1%5% | — | COMPLETED | 2015-10 | NCT02595034 |
| Sun Pharmaceutical Industries, Inc. | Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% | — | COMPLETED | 2015-08 | NCT02578043 |
| GSK | 0.3% GSK1940029 gel | — | COMPLETED | 2015-04-10 | NCT01984801 |
| AbbVie | AGN-190168 Formulation 1 | — | COMPLETED | 2015-03 | NCT02218034 |
| GSK | 0.3% GSK1940029 gel | — | COMPLETED | 2015-02-17 | NCT01938482 |
| Sun Pharmaceutical Industries, Inc. | Adapalene Gel 0.3% | — | COMPLETED | 2015-02 | NCT02411942 |
| Sun Pharmaceutical Industries, Inc. | Tazarotene Cream 0.1% | — | COMPLETED | 2015-01 | NCT02411955 |
| Vyne Therapeutics Inc. | FMX101, Minocycline 4% foam | — | COMPLETED | 2014-12 | NCT02250859 |
| Novan, Inc. | SB204 | — | COMPLETED | 2014-09 | NCT02250430 |
| Novan, Inc. | SB204 | — | COMPLETED | 2014-06 | NCT02164084 |
| Sun Pharmaceutical Industries, Inc. | Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% | — | COMPLETED | 2014-02 | NCT01742637 |
| Galderma R&D | CD0271 0.1%/CD1579 2.5% gel | — | COMPLETED | 2013-09 | NCT01688531 |
| Sun Pharmaceutical Industries, Inc. | Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% | — | COMPLETED | 2013-09 | NCT01769235 |
| GSK | Isotretinoin: Reference Medication 1 | — | COMPLETED | 2013-07-15 | NCT02498288 |
| Dermira, Inc. | Red Light (PDT) | — | COMPLETED | 2013-06 | NCT01830764 |
| Novan, Inc. | NVN1000 4% Gel | — | COMPLETED | 2013-06 | NCT01844739 |
| Sun Pharmaceutical Industries, Inc. | Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel | — | COMPLETED | 2013-06 | NCT01769664 |
| AbbVie | Dapsone Formulation A | — | COMPLETED | 2013-05-05 | NCT01773122 |
| Novan, Inc. | 2% NVN1000 Topical Gel | — | COMPLETED | 2012-11 | NCT01694810 |
| Novan, Inc. | Topical Gel Vehicle | — | COMPLETED | 2012-11 | NCT01755247 |
| GSK | GSK2585823 | — | COMPLETED | 2012-06-01 | NCT01527123 |
| Janssen Pharmaceutical K.K. | JNJ 10229570-AAA 1.2% | — | COMPLETED | 2011-10 | NCT01492647 |
| GSK | GSK2585823 | — | COMPLETED | 2011-02-15 | NCT01428466 |
| Stiefel, a GSK Company | Tazarotene Foam | — | COMPLETED | 2010-06-26 | NCT01114841 |
| Stiefel, a GSK Company | Tazarotene (Patch application in Challenge Phase) | — | COMPLETED | 2010-06-26 | NCT01119651 |
| Stiefel, a GSK Company | Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel, | — | COMPLETED | 2010-06-12 | NCT01132443 |
| Stiefel, a GSK Company | Tazarotene Foam | — | COMPLETED | 2010-04-26 | NCT01112787 |
| Stiefel, a GSK Company | Tazarotene Foam without irradiation | — | COMPLETED | 2010-04-10 | NCT01115322 |
| Medivet Pty Ltd | ProOxy | — | COMPLETED | 2010-03 | NCT01682200 |
| Stiefel, a GSK Company | Tazarotene | Retinoid [EPC] | COMPLETED | 2009-12-20 | NCT01019603 |
| GSK | clindamycin1%/tretinoin 0.025% gel | — | COMPLETED | 2009-02-20 | NCT01915758 |
| Stiefel, a GSK Company | CT Gel (clindamycin 1% and tretinoin 0.025%) | — | COMPLETED | 2008-12-19 | NCT01929278 |
| AbbVie | Dapsone Formulation A | — | WITHDRAWN | 2013-10 | NCT01785836 |
| AbbVie | Fixed Combination dapsone/adapalene Formulation A Gel | — | WITHDRAWN | 2013-06 | NCT01425320 |
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Acne
Novel Acne Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (4 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Generic Drugs (13 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
AMNESTEEM
Viatris
CLARAVIS
Teva
DROSPIRENONE AND ESTRADIOL
NOVAST LABS LTD
DROSPIRENONE AND ETHINYL ESTRADIOL
Teva
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM
WATSON LABS
ISOTRETINOIN
Teva
LO-ZUMANDIMINE
Aurobindo Pharma
LORYNA
XIROMED
MELAMISA
NOVAST LABS LTD
MYORISAN
UPSHER SMITH LABS
NIKKI
Lupin
YAELA
NOVAST LABS LTD
ZENATANE
Dr. Reddy's
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs